18.4% CAGR for Genome Editing Market Worth $16.98 Billion, Globally, by 2028 Lead by CRISPR Segment During 2021-2028 | The Insight Partners


North American region is the largest shareholder in the global genome editing market, the increasing prevalence of genetic disorders and adoption of advanced gene therapy for the treatment of chronic diseases is expected to drive the market in the country during 2021-2028.

Pune, India, June 23, 2023 (GLOBE NEWSWIRE) — According to our latest study on “Genome Editing Market Size Report, Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End User,” the market size is projected to reach $16.98 billion by 2028; which was valued at $5.19 billion in 2021 and; it is estimated to register a CAGR of 18.4% from 2021 to 2028. The major players covered in this study are Thermo Fisher Scientific Inc; Merck KGaA; Lonza; Horizon Discovery Group plc; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine.


Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPHE100000853

Global Genome Editing Market Strategic Insights:

Report Coverage Details
Market Size Value in USD 5.19 Billion in 2021
Market Size Value by USD 16.98 Billion by 2028
Growth rate CAGR of 18.4% from 2021 to 2028
Forecast Period 2021-2028
Base Year 2021
No. of Pages 176
No. of Tables 84
No. of Charts & Figures 76
Historical data available Yes
Segments covered Technology, Application, and End User
Regional scope North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scope US, Canada, Mexico, UK, Germany, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Browse key market insights spread across 176 pages with 84 list of tables & 76 list of figures from the report, “Genome Editing Market Size and Forecast to 2028 – COVID-19 Impact and Global Analysis by Technology (CRISPR, TALEN, Antisense, and Other); Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, And Others), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/genome-editing-market

Global Genome Editing Market: Competitive Landscape and Key Developments:
Thermo Fisher Scientific Inc.; MERCK KGaA; Lonza; Horizon Discovery Group plc.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics and Editas Medicine are among the key companies operating in the Genome Editing market. Leading players are adopting strategies such as the launch of new products, expansion and diversification of their market presence, and acquisition of new customer base for tapping prevailing business opportunities.

In March 2021, Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced that the acquisition of Swift Biosciences, a pioneer in the development of Next-Generation Sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research.

Speak To Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100000853

Continuous Technological Advancements in Gene Editing Tools:
Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability since they are precise, relatively inexpensive, easy to use, and remarkably powerful. The advances in genome editing can be traced back to quiet beginnings in the 1990s. The introduction of CRISPR-Cas9—a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease—is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform’s ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing could have a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to these advancements.

A team from MIT and Harvard’s Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers. Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture.

Recognizing the potential of genome editing techniques for studying and manipulating the genome, the DBT has been fostering research and innovation in genome engineering technologies and applications to make them more accessible and inexpensive for research and development (R & R&D). Through focused calls for proposals in different areas such as the development of new methods, tools, processes, and platforms for genome editing, improvement of existing genome-editing methods, and novel applications of genome editing technologies in agriculture, bioenergy, environmental research, and human health, efforts have been made to encourage R&D programs in emerging genome engineering technologies and their applications. Despite contributing to one-third of all deaths worldwide, there is no effective treatment, to date, for fibrosis. This study has established PAI-1 as a novel drug target, and pharmacologically targeting this protein may be an effective treatment for combating fibrosis. These factors for CRISPR system research are likely to favor the market’s growth.

Purchase Premium Copy of Genome Editing Market Growth Report (2021-2028) at: https://www.theinsightpartners.com/buy/TIPHE100000853

Global Genome Editing Market: End User Overview
The global genome editing market, based on end user is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations (CRO’s). In 2021, the pharmaceutical and biotechnology companies segment is likely to hold the largest share of the market. Moreover, the segment is also expected to witness growth in its demand at a fastest CAGR of 18.9% during 2021 to 2028, owing to the rise in the detection and diagnosis of various medical conditions across the globe.

The rise in the market for the biotechnological products and various related market has resulted into the enormous market consolidations in between biotechnology and pharmaceutical companies for the enhanced and better treatment options. The growing investments made by companies have grown the pharmaceutical & biotechnology companies segment in the market. For instance, in October 2020, Merck signed agreements licensing its CRISPR technology to two companies PanCELLa, a cell therapy company based in Toronto, Canada and Takara Bio USA, Inc.

The technological development in the molecular biology increased the sequencing procedures. Among the market leaders the companies have manufactured and designed technologically advanced NGS technology in last few years and various collaborations, investments made by the companies and the technological advancements have grown the pharmaceutical & biotechnology companies segment in genome editing market.

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Digital Genome Market Forecast to 2027 – COVID-19 Impact and Global Analysis

Whole Genome Amplification Market Forecast to 2028 – COVID-19 Impact and Global Analysis

Single-Cell Genome Sequencing (SCGS) Market Forecast to 2028 – Covid-19 Impact and Global Analysis

Genomic Biomarkers Market Forecast to 2028 – COVID-19 Impact and Global Analysis

Gene Therapy Market Forecast to 2028 – COVID-19 Impact and Global Analysis

CRISPR Technology Market Forecast to 2028 – Covid-19 Impact and Global Analysis

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/genome-editing-market
Industry Research: https://www.biospace.com/employer/2735308/the-insight-partners/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.